405 related articles for article (PubMed ID: 32865839)
1. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
Miyahira AK; Pienta KJ; Babich JW; Bander NH; Calais J; Choyke P; Hofman MS; Larson SM; Lin FI; Morris MJ; Pomper MG; Sandhu S; Scher HI; Tagawa ST; Williams S; Soule HR
Prostate; 2020 Nov; 80(15):1273-1296. PubMed ID: 32865839
[TBL] [Abstract][Full Text] [Related]
2. Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
Miyahira AK; Pienta KJ; Morris MJ; Bander NH; Baum RP; Fendler WP; Goeckeler W; Gorin MA; Hennekes H; Pomper MG; Sartor O; Tagawa ST; Williams S; Soule HR
Prostate; 2018 Aug; 78(11):775-789. PubMed ID: 29717499
[TBL] [Abstract][Full Text] [Related]
3. Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.
Iravani A; Violet J; Azad A; Hofman MS
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):38-52. PubMed ID: 31595044
[TBL] [Abstract][Full Text] [Related]
4. Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.
Emmett L
Semin Oncol Nurs; 2020 Aug; 36(4):151052. PubMed ID: 32674976
[TBL] [Abstract][Full Text] [Related]
5. The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation.
Miyahira AK; Soule HR
J Nucl Med; 2022 Mar; 63(3):331-338. PubMed ID: 34675109
[TBL] [Abstract][Full Text] [Related]
6. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.
Oprea-Lager DE; MacLennan S; Bjartell A; Briganti A; Burger IA; de Jong I; De Santis M; Eberlein U; Emmett L; Fizazi K; Gillessen S; Herrmann K; Heskamp S; Iagaru A; Jereczek-Fossa BA; Kunikowska J; Lam M; Nanni C; O'Sullivan JM; Panebianco V; Sala E; Sathekge M; Sosnowski R; Tilki D; Tombal B; Treglia G; Tunariu N; Walz J; Yakar D; Dierckx R; Sartor O; Fanti S
Eur Urol; 2024 Jan; 85(1):49-60. PubMed ID: 37743194
[TBL] [Abstract][Full Text] [Related]
7. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Theranostics: PSMA Targeted Therapy.
Seifert R; Alberts IL; Afshar-Oromieh A; Rahbar K
PET Clin; 2021 Jul; 16(3):391-396. PubMed ID: 34053583
[TBL] [Abstract][Full Text] [Related]
9. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
Plichta KA; Graves SA; Buatti JM
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829977
[TBL] [Abstract][Full Text] [Related]
10. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
Ilhan H; la Fougère C; Krause BJ
Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
[TBL] [Abstract][Full Text] [Related]
11. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
12. The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey.
Borkowetz A; Linxweiler J; Fussek S; Wullich B; Saar M;
Urol Int; 2022; 106(11):1126-1135. PubMed ID: 36195073
[TBL] [Abstract][Full Text] [Related]
13. PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.
Debnath S; Zhou N; McLaughlin M; Rice S; Pillai AK; Hao G; Sun X
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163083
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. A 2022 International Survey on the Status of Prostate Cancer Theranostics.
Beyer T; Czernin J; Freudenberg L; Giesel F; Hacker M; Hicks RJ; Krause BJ
J Nucl Med; 2023 Jan; 64(1):47-53. PubMed ID: 35953304
[TBL] [Abstract][Full Text] [Related]
16. Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics.
Eshghi A; Covington MF; Eshghi N; Kuo PH
Clin Nucl Med; 2022 Jun; 47(6):488-495. PubMed ID: 35384904
[TBL] [Abstract][Full Text] [Related]
17. Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
Sandhu S; Guo C; Hofman MS
J Nucl Med; 2021 Aug; 62(12):1660-8. PubMed ID: 34385339
[TBL] [Abstract][Full Text] [Related]
18. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
19. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
20. PSMA Theranostics: Current Status and Future Directions.
Rahbar K; Afshar-Oromieh A; Jadvar H; Ahmadzadehfar H
Mol Imaging; 2018; 17():1536012118776068. PubMed ID: 29873291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
